, Volume 28, Issue 12, pp 5-8
Date: 18 Dec 2012

Current evidence supports the use of combination therapy in the management of benign prostatic hyperplasia

  • show all 0 hide

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Current evidence supports the use of an α1-adrenergic receptor antagonist in combination with a 5α-reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia (BPH). The combination of an α1-adrenergic receptor antagonist plus a cholinergic receptor antagonist is an option for the treatment of lower urinary tract symptoms suggestive of BPH.

Very common in older men

Benign prostatic hyperplasia (BPH), a very common condition in older men, is caused by unregulated proliferation of smooth muscle and epithelial cells within the transition zone of the prostate.[1] Unregulated cellular proliferation leads to increased stromal smooth muscle tone and prostate volume, which in turn leads to physical compression of the urethra and mechanical obstruction of the bladder outlet. This can result in the following lower urinary tract symptoms (LUTS):[1,2]

  • storage symptoms (e.g. frequency, nocturia, urgency);

  • voiding symptoms (e.g. hesitancy, straining);

  • post-micturition symptoms (e.g